Alcon has signed a US$60 million agreement to acquire Kala Pharmaceuticals’ loteprednol etabonate products Eysuvis 0.25% for dry-eye disease (DED) and Inveltys 1%, for post-operative inflammation and pain.
Eysuvis was approved by the FDA in January 2021 as the only corticosteroid indicated for up to two weeks’ DED treatment. It uses Ampplify, a delivery technology designed to enhance ocular surface penetration of loteprednol etabonate. Eysuvis complements the Systane range of eye drops, including the recently launched preservative-free formulations, said Alcon in a statement.
Revenues for Eysuvis and Inveltys in 2021 were US$6.3 million and US$4.9 million, respectively. The transaction is expected to be completed later this year, subject to regulatory approval.
